Bristol-Myers Squibb Co. (BMY) has sought FDA approval for the expanded use of its drug Reblozyl for first-line treatment of anemia in low-to- intermediate-risk myelodysplastic syndrome patients, and the decision is due on August 28, 2023.Myelodysplastic Syndromes (MDS) encompass a collection of blood disorders characterized by genetic mutations that hinder the bone marrow's ability to produce blood stem cells responsible for the formation of normal and healthy blood cells.As a result of the reduced presence of mature red blood cells (RBCs), individuals with MDS often suffer from severe and persistent anemia, requiring regular transfusions of red blood cells.Approximately 87,000 new cases of MDS are diagnosed every year, according to the company.Reblozyl is already approved for the treatment of anemia in MDS patients who fail an erythropoiesis stimulating agent. The drug, which received its initial FDA approval in November 2019, generated annual sales of $717 million in 2022, and $206 million in the first quarter of 2023.BMY closed Friday’s (Jul.28, 2023) trading at $61.41, up 1.12%.